10-Q quarterly report · filed Nov 9, 2026

Immunovant, Inc. (IMVT) Q3 2026 10-Q Quarterly Report

Short answer

Immunovant, Inc. (IMVT) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$97M
+23.1% YoY · +36.5% QoQ
EPS (diluted)
−$0.47
+34.7% YoY · +37.3% QoQ

Source: XBRL data from the Immunovant, Inc. (IMVT) Q3 2026 10-Q on SEC EDGAR. USD.

Immunovant, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, reflecting no commercialized products
  • Net loss $97.2M vs $126.5M YoY, operating expenses $104.2M vs $131.8M
  • Best R&D area, endocrine $22.5M; worst, neurological $18.3M, both down YoY
  • Cash $722.3M vs $902.1M at March 31; operating cash used $207.6M
  • Cash expected to fund operations through potential GD launch; expanded development could shorten runway

Risk Factors

  • No material risk-factor changes during quarter ended September 30, 2026
  • Carried-forward risks include potential adverse effects on business, operations, financial condition and cash flows
  • Share-price risk: adverse events could reduce Immunovant common-stock value
  • Investment risk: shareholders could lose all or part of their investment

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Immunovant, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.